333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer
| Autor: | Campone, M., Bardia, A., Kabos, P., Chandarlapaty, S., Neven, P., Boni, V., Lord, S., Cartot-Cotton, S., Celanovic, M., Gosselin, A., Pelekanou, V., Linden, H.M. |
|---|---|
| Zdroj: | In Annals of Oncology September 2021 32 Supplement 5:S511-S512 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|